News zum Sektor Gesundheit aus Norwegen

 

Oslo, Norway, 13 January 2026: Reference is made to the announcement made by Oncoinvent ASA ("Oncoinvent" or the "Company") 31 October 2025 regarding the appointment of Ramzi Amri as the new CEO of the Company as of January 2026. The Board of Directors has resolved to grant Ramzi Amri 5,430,000 share options in the Company under the Company's long term incentive program, each with a strike price of NOK 0.4671, equal to the volume weighted average share price the last day before the grant. Following the grant of the 5,430,000 share options referred to above, Ramzi Amri hold no shares and 5,...

Press release – Oslo, Norway, January 12th, 2026: Photocure announces the publication of the study “Hexaminolevulinate blue light cystoscopy improves bladder cancer detection in comparison to white light cystoscopy: a prospective, comparative, within-patient controlled multicenter phase III bridging study in China” in the Frontiers of Urology journal this week. An abstract with data from this pivotal prospective randomized controlled multi-center Phase 3 trial was first presented at the Congress of the Société Internationale d'Urologie (SIU) in October 2023. Its main objective was to compare...

Oslo (Norway), 8 January 2026 – PCI Biotech (OSE: PCIB). Reference is made to the company's latest announcement dated 23rd October 2025. The external evaluation of a new bioprocessing technology has been concluded, with no prospects for further collaboration. As PCI Biotech's limited operations were contingent upon sustained external interest, all R&D operations will now be discontinued....

Oslo, Norway, 8 January 2026: An extraordinary general meeting of the Company was held today, 8 January 2026, by electronic means through Lumi AGM. The general meeting, inter alia, resolved i) audited interim balance sheet, ii) a reverse share split, iii) a capital reduction, and iv) proxy to the Board of Directors. The complete minutes of the extraordinary general meeting are attached to this release and are also available on the Company's website, https://www.oncoinvent.com/. Please see Minutes from EGM here.  (https://mb.cision.com/Public/15728/4289947/9ff32e60041f91f5.pdf) (https:/...

Grete Roede og Navamedic inngår et samarbeid om en ny, strukturert metode for vektreduksjon. Det første konseptet, Lettere steg, lanseres i romjulen 2025 og fortsetter inn i 2026. Konseptet legger vekt på fellesskap, støtte og erfaringsdeling underveis i prosessen. Hele Norges «slankedronning» Grete Roede grunnla selskapet for å hjelpe nordmenn med å få kontroll over vekten. I dag ledes selskapet av datteren Jeanette Roede og tilbyr personlig veiledning, kurs og digitale løsninger gjennom blant annet Grete Roede-appen. – I Grete Roede har vi alltid vært opptatt av forskningsbaserte og...

Oslo, Norway, 22 December 2025: Oncoinvent ASA (“Oncoinvent” or the “Company”) (OSE: ONCOIN), a clinical stage, radiopharmaceutical company developing innovative treatments for solid cancers, today announce that the Board of Directors has granted options to employees. As previously communicated and with the objective of aligning share option participants' interests with those of the shareholders of the Combined Company, the Board of Directors has established a replacement share option and RSU program for employees and board members similar to Oncoinvent's program before the merger with...

Oslo, 19 December 2025 – Observe Medical ASA (the "Company" or "Observe Medical", OSE ticker "OBSRV") has received a loan commitment from Innovation Norway for a loan of NOK 15 million to support the continued commercialisation of the Company's UnoMeter™ product portfolio, and commercial preparation for the launch of Sippi®. The availability of the loan is subject to execution of final loan documentation and certain customary conditions precedent. Further information regarding final terms and drawdown will be provided once the loan agreement has been executed. Jørgen Mann, CEO of...

Oslo, Norway, 17 December 2025 – Zelluna (OSE: ZLNA), a company pioneering allogeneic off-the-shelf cell therapies for cancer, today announced the submission of its Clinical Trial Application (CTA) to the UK Medicines and Healthcare products Regulatory Agency (MHRA) for ZI-MA4-1, the Company's lead candidate....

Reference is made to the stock exchange release published by Arctic Bioscience 12th December 2025 regarding Board approval of share capital increase related to the exercise of debt conversion rights and corresponding issuance of new shares in Arctic Bioscience. The share capital increase has now been registered with the Norwegian Register of Business Enterprises. As a result, the new share capital of Arctic Bioscience has increased from NOK 2 685 934 to NOK 2 695 625,60, divided into 26 956 256 shares, each having a nominal value of NOK 0,10. This information is subject to the disclosure...

Helsinki, Finland, 16 December 2025: Oy Pasanen & Co, a close associate of Valter Pasanen, a primary insider of Nordhealth AS (the "Company"), has today converted 402,796 Class B shares in the Company to Class A shares. Following registration of the conversion, the Company has a share capital of NOK 80,191,746, divided into 45,594,543 Class A shares and 34,597,203 Class B shares, each with nominal value of NOK 1.00. Each Class A share carries one vote and each Class B share carries 10 votes. Please refer to the attached notification of trading for further details. For further...

Oslo, Norway, 16 December 2025– Zelluna (OSE: ZLNA), a company developing off-the-shelf cell therapies for cancer, today announced the publication of preclinical data for its lead candidate, ZI-MA4-1, in the peer-reviewed journal Immunotherapy Advances*. The data support the company's plan to start clinical trials in 2026....

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, JAPAN OR THE UNITED STATES OR ANOTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN....

Um den gesamten Artikel unter 4investors.de zu lesen, klicken Sie bitte auf die Überschrift...

Reference is made to the stock exchange release published by Arctic Bioscience 9th December 2025 regarding exercise of right to convert debt and corresponding issuance of new shares in Arctic Bioscience. On 12 December 2025, the Board of Arctic Bioscience, on the basis of a board authorization granted by the Company's General Meeting on 26[th] May 2025, resolved to increase the share capital from NOK 2 685 934 to NOK 2 695 625,60 by issuance of 96 916 new shares with a nominal value of NOK 0,10 per share, at a subscription price of NOK 2,789659405 per share, including a share premium of NOK...

Oslo, Norway, 12 December, 2025 – Zelluna (OSE: ZLNA), a company pioneering allogeneic “off-the-shelf” T Cell Receptor-based Natural Killer (TCR-NK) cell therapies for the treatment of cancer, today announced the successful manufacture and QC (Quality Control) testing of the first GMP (Good Manufacturing Practice) batch of its lead candidate, ZI-MA4-1. This material is intended for use in Zelluna's upcoming first-in-human clinical trial, marking a major milestone in the company's progress toward regulatory submission and patient dosing....

Oslo, 12 December 2025 – Observe Medical ASA (the "Company" or "Observe Medical") announces expansion of portfolio, progress on commercial journey and in the development of UnoMeter™ Safeti™ Max. The Company is launching an extension of its portfolio of products within the category of Urological Drainage. The launch includes 3 new products: a front mounted UnoMeter which is a preference in some markets and 2 Closed System products which are sterile solutions used widely within hospitals globally. In combination it is estimated the global market value of these products are at a level of 1,...

10 December 2025: Reference is made to the stock exchange announcements published by Oncoinvent ASA (the "Company") on 30 June 2025 and 4 August 2025, and subsequent announcements, regarding the contemplated fully underwritten rights issue of 260,000,000 new shares in the Company (the "Offer Shares") raising gross proceeds of NOK 130 million (the "Rights Issue"). Further, reference is made to the stock exchange announcement published by the Company on 5 December 2025 regarding the resolution by the board of directors of the Company to issue 31,199,997 new shares in the Company, each with a...

Navamedic ASA is excited to announce the launch of Flexilev[®] in OraFID[®], a novel, single-use dosing dispenser specifically designed to deliver precise and personalized Parkinson's treatment in a user-friendly format. The product will be available for prescription at pharmacies late December/early January. As Parkinson's disease advances, patients frequently experience variations in motor abilities throughout the day. For those facing reduced efficacy towards the end of the dosing interval (dose gaps) the OraFID[®] dispenser provides an enhanced opportunity to fine tune levodopa treatment....

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN OR ANY JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL....

With reference to the stock exchange notice of 13[th] of January 2025 regarding new financing via a convertible loan. An investor, which participated in the investor consortium contributing to the convertible loan of total NOK 15 million, has exercised his right to convert the outstanding debt into shares. Debt that will be converted is NOK 270 365. The conversion amount includes accrued interest. The conversion price is set at NOK 2,7896 per share based on the received conversion notice. The Board of Directors will issue the shares, pursuant to authorization granted by the Company's General...